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Drug discovery and development
Broad-spectrum antiviral agents
BSAAs
A B S T R A C T
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific
vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-
spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral
families) could provide additional protection of the general population from emerging and re-emerging
viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and
development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible
database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the
number of BSAAs, expand the spectrum of their indications, and identify drug combinations for
treatment of emerging and re-emerging viral infections as well as co-infections.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Viruses are one of the major causes of morbidity and mortality
in the world (DALYs and Collaborators, 2018; Disease et al., 2018;
Howard and Fletcher, 2012; WHO, 2015). Antiviral drugs and
vaccines are used to fight viral infections in human (De Clercq and
Li, 2016; Marston et al., 2014). Previously, there has been a focus on
“one drug, one virus” dogma, which relied on targeting virus-
specific factors. A counterpoint to this is the “one drug, multiple
viruses” paradigm, which came with the discovery of broad-
spectrum antiviral agents (BSAAs), small-molecules that inhibit a
wide range of human viruses (Bekerman and Einav, 2015; de Clercq
and Montgomery, 1983; Debing et al., 2015; Ianevski et al., 2019;
Rada and Dragun, 1977; Sidwell et al., 1972). This paradigm was
based on the observation that different viruses utilize similar
pathways and host factors to replicate inside a cell (Bosl et al.,* Corresponding author at: Department of Clinical and Molecular Medicine,
Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
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(http://creativecommons.org/licenses/by/4.0/).2019). Although the concept of BSAAs has been around for almost
50 years, the field received a new impetus with recent outbreaks of
Ebola, Zika, Dengue, influenza and other viral infections, the
discovery of novel host-directed agents, as well as development of
drug repositioning methodology.
Drug repurposing, also called repositioning, redirecting,
reprofiling, is a strategy for generating additional value from an
existing drug by targeting disease other than that for which it was
originally intended (Nishimura and Hara, 2018; Pushpakom et al.,
2019). This has significant advantages over new drug discovery
since chemical synthesis steps, manufacturing processes, reliable
safety, and pharmacokinetic properties in pre-clinical (animal
model) and early clinical developmental phases (phase 0, I and IIa)
are already available (Figure 1). Therefore, repositioning of
launched or even failed drugs to viral diseases provides unique
translational opportunities, including a substantially higher
probability of success to market as compared with developing
new virus-specific drugs and vaccines, and a significantly reduced
cost and timeline to clinical availability (Ianevski et al., 2019;
Pizzorno et al., 2019; Zheng et al., 2018).
Here, we detail the steps of BSAA repurposing, from discovery of
novel antiviral activities in cell culture to post-market studies.ciety for Infectious Diseases. This is an open access article under the CC BY license
Figure 1. Discovery of novel activities and follow-up development of broad-spectrum antiviral agents (BSAAs). Yellow shading indicates a process of discovery and
development of safe-in-man BSAAs, for which pharmacokinetic (PK) properties in pre-clinical (animal model) and early clinical developmental phases (phase 0-IIa trials) are
already available. Abbreviations: ESCs, human embryonic stem cells; iPSCs, human induced pluripotent stem cells (iPSCs).
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BSAAs in freely available database, focusing on those antivirals,
which have been already tested in human as antivirals, anti-
bacterials, antiprotozoals, anthelmintics, etc. Finally, we discuss
future perspectives of using safe-in-man BSAAs for treatment of
emerging and re-emerging viral infections as well as viral and
bacterial co-infections.
Discovery and development of safe-in-man BSAAs
Discovery of novel BSAA activities in immortalized cell cultures and
co-cultures
The discovery of novel activities of BSAAs starts with exposing
cells to the candidate antiviral agent at different concentrations
and infecting the cells with a virus or mock. Immortalized
cancerous cell cultures and co-cultures, which express appropriate
viral receptors, are most commonly used in this first step. The half-
maximal cytotoxic concentrations (CC50) for a compound are
calculated based on their dose-response curves obtained on mock-
infected cells. The half-maximal effective concentrations (EC50) are
calculated based on the analysis of curves obtained on infected
cells. Statistical analyses can help to determine if the differences
between CC50 and EC50 are significant, given the inherent
variability of the experiment (Meneghini and Hamasaki, 1967).
A relative effectiveness of a drug is defined as selectivity index
(SI = CC50/EC50).
Cell viability assays and cell death assays are commonly used to
assess the cytotoxicity and efficacy of BSAAs (Figure 2A). Cell
viability assays include MTT, MTS, resazurin or similar assays,
mitochondrial membrane potential-dependent dyes-based assays,
esterase cleaved dye-based assays, ATP-ADP assays, and assays that
measure glycolytic flux and oxygen consumption. Other cell death
assays include LDH enzyme leakage assays, membrane imperme-
able dye-based assays, and apoptosis assays, such as Annexin V,
TUNEL, and caspase assays (Shen et al., 2019). For example, the Cell
Titer Glo (CTG) assay quantifies ATP, an indicator of metabolically
active living cells, whereas Cell Tox Green assay uses fluorescent
asymmetric cyanine dye that stains the DNA of dead cells (Bosl
et al., 2019; Bulanova et al., 2017; Ianevski et al., 2018; Muller et al.,
2014).
Viral strains or cell lines expressing reporter proteins are also
used to assess the efficacy of BSAAs in infected cells. For example,
TZM-bl cells expressing firefly luciferase under control of HIV-1
LTR promoter allowed quantitation of BSAA action on HIV-1
infection (tat-protein expression by integrated HIV-1 provirus)
using firefly luciferase assay (Sarzotti-Kelsoe et al., 2014; Xing
et al., 2016). RFP-expressing RVFV, nanoLuc-expressing CHIKV and
RRV, as well as GFP-expressing FLUAV, HCV and HMPV also allowed
identification of novel activities of several BSAAs (Andersen et al.,
2019b; Bosl et al., 2019; de Graaf et al., 2007; Habjan et al., 2008;
Ianevski et al., 2018; Jupille et al., 2011; Kittel et al., 2004; Lee et al.,
2017; Utt et al., 2016). In addition, qPCR/RT-qPCR, RNA/DNA
sequencing, RNA/DNA hybridization, immuno- and plaque assays
as well as CRISPR-Cas9 systems could be used for detection ofinhibitory effects of BSAAs (Boonham et al., 2014; Fischer et al.,
2017; Konig et al., 2019; Laamiri et al., 2018; Landry, 1990; Perez
et al., 2013; Sashital, 2018; Zhou et al., 2018). Interestingly, CRISPR-
Cas9, siRNA and shRNA approaches were used for identification of
BSAA targets (Deans et al., 2016; Puschnik et al., 2017).
Novel anti-HSV-2 and anti-EV1 activities of emetine were
discovered recently using CTG/plaque assays in human non-
malignant RPE cells. Moreover, novel antiviral activities of the drug
were identified using RFP-expressing RVFV, and GFP-expressing
HMPV or FLUAV strains in RPE cells (Andersen et al., 2019a). Given
that emetine also inhibits ZIKV, EBOV, RABV, CMV, HCoV-OC43 and
HIV-1 infections (Chaves Valadao et al., 2015; MacGibeny et al.,
2018; Mukhopadhyay et al., 2016; Shen et al., 2019; Yang et al.,
2018), and that it is an FDA-approved anti-protozoal drug, it may
represent a promising safe-in-man BSAA candidate.
Evaluation of BSAAs in human primary cell culture and co-cultures
Immortalized cell cultures/co-cultures and reporter viral
strains represent excellent model systems for the discovery of
novel activities of safe-in-man BSAAs. However, these genetically
modified systems have certain limitations (attenuated or incom-
plete virus replication cycle, accumulation of mutations during
repeated cell and virus passaging, defective innate immune
responses and viral counter-responses, etc.) (Carter and Shieh,
2015). Thereby, novel antiviral activities of BSAAs should be further
validated in primary human cells using different viral strains
(including wild-type viruses), different viral loads, different times
of compound addition, different endpoint measurements and
compound concentration range. Primary cell cultures give more
accurate images of drug responses (Alves et al., 2018; Denisova
et al., 2012; Koban et al., 2018; Postnikova et al., 2018). They have a
low population doubling level and therefore more closely
recapitulate the physiological conditions observed in vivo.
Primary cells are cells isolated directly from tissues or blood
using enzymatic or mechanical methods. The cells are character-
ized by their high degrees of specialization, are often fully
differentiated and thus require defined culture conditions (se-
rum-free media) in order to preserve their original phenotype.
Peripheral blood mononuclear (PBMC), placental, amniotic and
fetal primary cultures as well as vaginal/cervical epithelial and
male germ cells have been used intensively to validate BSAA
activity (Barrows et al., 2016; Denisova et al., 2012; Fink et al., 2018;
Rausch et al., 2017; Robinson et al., 2018). Although primary cell
cultures are relevant systems for validation of BSAAs, there are
technical difficulties limiting their use, such as ethical issues,
purity of population of primary cells, and limited shelf life of the
cells. In addition, age, race, sex and other genetic and epigenetic
factors of donor cells should be considered to determine common
biological effect across a significant number of donors thereby
avoiding minor variants (Lee et al., 2014; Zhang et al., 2013).
The obstacles associated with use of human primary cell
cultures can be bypassed using human embryonic stem cells (ESCs)
and human induced pluripotent stem cells (iPSCs). ESCs are
isolated from surplus human embryos, whereas iPSCs are obtained
Figure 2. ABC of BSAA development process. (A) Testing BSAA toxicity (left panel) and efficacy (right panel) in immortalized cell cultures and co-cultures. (B) Testing BSAA
toxicity (left panel) and efficacy (right panel) in animal models. If BSAA is repositioned from another disease (i.e. its PK/PD and toxicity profiles are available for the animal
model) it could bypass the safety studies. (C) Clinical trials of BSAAs. (Left panel) Pharmacokinetics (PK) and safety studies. (Right panel) Efficacy studies. If the drug is
repositioned from another disease (i.e. its safety profile in man is available) it could bypass the PK and safety studies in man.
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and retain multi-lineage activity, which allows them to generate
virtually any cell type of the body. The ESCs- and iPSC-derived cells
have been used successfully to investigate the efficacy of several
BSAAs against HBV, ZIKV, CHIKV and HSV-1 infections (Table S1)
(Ferreira et al., 2019; Iwasawa et al., 2019; Lanko et al., 2017;
Simonin et al., 2019; Xia et al., 2017; Zhou et al., 2017).
iPSCs, ESCs and primary tissue cells can be used to generate
complex cultures termed organoids. Organoids are miniature and
simplified version of organs. Establishing human airway, gut, skin,
cerebral, liver, kidney, breast, retina and brain organoids allowed
researchers to study toxicity and efficacy of several safe-in-man
BSAAs against coronaviruses, influenza, enteroviruses, rotaviruses
and flaviviruses (Li et al., 2017; Sacramento et al., 2017; Watanabe
et al., 2017; Xu et al., 2016; Yin et al., 2015; Yin et al., 2018; Yin et al.,
2016; Zhou et al., 2017). However, iPSCs, ESCs and iPSCs/ESCs-
derived organoids have the same disadvantages as human primary
cells (genetic differences, line-to-line and organoid batch-to-batchvariability). On the other hand, these models allow researchers to
predict the behavior of viruses in vivo and, therefore, to reduce
animal use and in cases where animal models are unavailable to
initiate clinical trials.
For example, novel anti-ZIKV activities of enoxacin, amodia-
quine and niclosamide were discovered recently using human
neural progenitor cells, human pluripotent stem cell-derived
cortical neural progenitor cells, and human induced neural stem
cells, respectively (Cairns et al., 2018; Xu et al., 2019; Zhou et al.,
2017). Enoxacin is an oral broad-spectrum fluoroquinolone
antibiotic, which also possesses anti-HCV and anti-HIV-1 activities
in immortalized cell cultures (Kashiwase et al., 1999; Young et al.,
2010). Amodiaquine is an anti-malaria drug, which also possesses
antiviral activities against DENV, HCV, RRV, SINV, WNV, EFV, EBOV,
LASV, RABV, VZV, and HSV-1 in immortalized cell cultures
(Boonyasuppayakorn et al., 2014; Hulseberg et al., 2019; Mazzon
et al., 2019). Niclosamide is an orally bioavailable anthelmintic
drug which inhibits the broadest range of viruses in vitro and, in
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et al., 2017; Hulseberg et al., 2019; Jurgeit et al., 2012; Kao et al.,
2018; Mazzon et al., 2019; Stachulski et al., 2011; Wang et al., 2016;
Wu et al., 2004). These safe-in-man BSAAs represent promising
drug candidates.
Evaluation of BSAAs in animal models
In vitro and ex vivo models do not fully reflect the complexity
and physiology of living organisms. Therefore, several in vivo
models have been developed to test novel antiviral activities of
BSAAs. These include immunocompetent and genetically or
chemically immunocompromised mice, guinea pigs, hamsters,
ferrets, pigs, macaques and other animals (Figure 2B) (Alves et al.,
2018; Haese et al., 2016; Louz et al., 2013; Morrison and Diamond,
2017; Taylor, 2017; Thangavel and Bouvier, 2014). PK/PD studies
determine drug absorption, dosage and half-life of BSAAs.
Toxicological studies determine if the drugs have any adverse
effects on the tissues and organs of the animals and define the
dosage of adverse effects (Alabaster and In Vivo Pharmacology
Training Group, 2002; Parasuraman, 2011; Rizk et al., 2017).
Studying the efficacy of BSAAs is generally done by treating the
animal with the drug or vehicle and infecting it with a virus of
interest. Endpoints are usually body weight/ mortality (depending
on the virus), histopathology, virus titers in organs, presence of
clinical signs and development of immunity (Oh and Hurt, 2016;
Smee and Barnard, 2013). Although animal models can give the
initial characterization of BSAA, it is important to keep in mind that
they differ significantly from humans, with respect to symptoms,
disease manifestation, susceptibility, immune responses, patho-
genesis, and pharmacokinetics (Barré-Sinoussi and Montagutelli,
2015; Shanks et al., 2009).
Often animals require higher concentration of an experimental
antiviral as compared to effective in vitro concentrations.
Moreover, it is relatively difficult to achieve micromolar EC50 in
vivo. For example, aminoglycoside antibiotics, kasugamycin and
neomycin were successfully tested against ZIKV, FLUAV, and HSV-2
infections in mice (Gopinath et al., 2018). Polyether antibiotic
salinomycin also showed anti-FLUAV effect in mice (Jang et al.,
2018). In addition, investigational anticancer agent, flavopiridol,
was effective against FLUAV in mice (Soderholm et al., 2016). These
findings support further development of these and other BSAAs.
Clinical trials and post-clinical studies of BSAAs
Clinical trials are the most critical and time-consuming step of a
drug candidates’ journey to being approved (Figure 2C). However,
safe-in-man BSAAs make this journey relatively short, because
they have been already at phase 0, I and, sometime, at IIa of clinical
trials as antibacterial, antiprotozoal, anticancer, etc. agent; i.e. they
have been administered at sub-therapeutic doses to healthy
volunteers to ensure the drugs are not harmful to the participants.
Thus, safe-in-man BSAAs enter phase II and III, which assess the
efficacy, effectiveness, safety and side effects of the drugs in clinic.
It is important, however, to differentiate acute and chronic viral
infections when repurposing BSAAs, given that drug concentra-
tions and duration of the treatment could be different, and
therefore, drug safety issues should be considered.
For phase II, patients with the viral disease in question are
invited to join the study, where they are administered the BSAAs at
the ideal therapeutic doses. Phase III is the longest of the phases,
and includes multiple levels of securities to the studies, such as the
use of placebos and double-blinded studies, to ensure the data is as
unbiased as possible. Upon completing phase III, depending on its
performance and efficacy, BSAAs may end either being approved or
dropped. The U.S Food and Drug Administration (FDA) estimatesthat only 25–30% BSAA candidates that enter phase III are approved
for use in the public (U.S Food and Drug Administration, 2018).
After approval and marketing of the drug, phase IV may be initiated
to follow up on the use of the drug in public, to surveil for rare
effects (U.S Food and Drug Administration, 2018; Umscheid et al.,
2011).
Forty-eight safe-in-man BSAAs undergo clinical studies as anti-
virals. There are currently 21 compoundsinphase I, 34 agents inphase
II and 11 compounds in phase III clinical trials. For example,
nitazoxanide, remdesivir and brincidofovir are under clinical inves-
tigations against different viral infections (NCT03336619,
NCT00302640, NCT03605862, NCT03719586, NCT01276756,
NCT03905655, NCT01529073, NCT03395405, NCT03216967,
NCT01431326, NCT02087306, NCT01769170).
Twenty-one BSAAs were approved by FDA, EMA or other
agencies. These BSAAs altogether target 15 viruses. For example,
favipiravir, also known as T-705, was approved against FLUAV in
Japan; cidofovir is an injectable antiviral medication used as a
treatment for CMV retinitis in people with AIDS; ribavirin, also
known as tribavirin, is used for treatment of RSV and HCV
infections; pleconaril is used against viruses in the picornavir-
idae family, including enterovirus and rhinovirus; and valacy-
clovir is used against CMV, EBV, HBV, HSV-1, HSV-2 and VZV
infections.
Twenty BSAAs are undergoing surveillance studies (phase IV).
Azithromycin, chloroquine, cyclosporine, ezetimibe, mycophenolic
acid, nitazoxanide and rapamycin progressed to phase IV studies
without approvals from national or international authorities
(NCT01779570, NCT02058173, NCT02564471, NCT00821587,
NCT03360682, NCT02328963, NCT02768545, NCT01624948,
NCT01770483, NCT02683291, NCT01624948, NCT01469884,
NCT03901001, NCT01412515, NCT02990312).
BSAA database
We have developed a database for safe-in-man BSAAs, which is
available at https://drugvirus.info/ (Figure 3). The drug annota-
tions were obtained from PubChem, DrugBank, DrugCentral,
PubMed and clinicaltrials.gov databases (Table S1) (Kim et al.,
2019; Ursu et al., 2019; Wishart et al., 2018). The information on
virus families was exported from Virus Pathogen Database and
Analysis Resource (Table S2) (Pickett et al., 2012). The database
summarizes activities and developmental status of BSAAs. We
decided to set no limits for EC50, SI and statistical significance
because the studies were not harmonized (different cell lines,
assays, end-point measurements, time of compound addition,
etc.). The database allows interactive exploration of virus-BSAA
interactions. It also includes information on BSA targets. A
feedback form is available on the website. The database will be
updated upon request or as soon as a new safe-in-man BSAA
emerges or novel activity for an existing BSAA is reported.
Altogether, the database contains 120 approved, investigational
and experimental safe-in-man BSAAs, which inhibit 86 human
viruses, belonging to 25 viral families. The BSAAs inhibit viral or
host factors and block viral replication, reduce the viral burden to a
level at which host immune responses can deal with it or facilitate
apoptosis of infected cells (Table S1). Analysis of BSAA targets and
structures (Figure 4) revealed that the most abundant are
nucleotide and nucleoside analogues which inhibit viral RNA
and DNA polymerases. Imatinib, erlotinib, gefitinib, and dasatinib,
which inhibit tyrosine kinases, are the most abundant host-
directed BSAAs. Most of the host targets (except Bcl-xL protein) are
essential for viral replication but redundant for the cell, which is
critical for reducing putative toxicities associated with blocking
cellular pathways. The limited diversity of the targets and scaffolds
could slow down the development of BSAA concept.
Figure 3. Safe-in-man broad-spectrum antiviral agents (BSAAs) and viruses they inhibit. A snapshot is taken from https://drugvirus.info/ website. Viruses are clustered by
virus groups. BSAAs range from the highest to lowest number of targeted viruses. Different shadings indicate different development status of BSAAs. Gray shading indicates
that the antiviral activity has not been either studied or reported. Abbreviations: ds, double-stranded; RT, reverse transcriptase; ss, single-stranded.
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Figure 4. Structure-activity relationship of safe-in-man BSAAs. Web-application serves C-SPADE was used to cluster BSAAs based on their structural similarities and visualize
them as a dendrogram of compounds augmented with their functional annotations (https://cspade.fimm.fi/).
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nylhalamide, and GS-5734 (Denisova et al., 2012; Kuivanen et al.,
2017; Muller et al., 2011; Muller et al., 2014; Patil et al., 2017;
Sheahan et al., 2017), whose safety profiles in humans are not yet
available, are not included in the database. However, they could
serve as valuable antivirals in the future, pending the results of
further pre-clinical and clinical investigations.
BSAAs as drug candidates for treatment of SARS-CoV-2
infections
SARS-CoV-2 is a novel strain of coronaviruses which is
associated with a cluster of cases of pneumonia in China (Zhou
et al., 2020). Coronaviruses (CoV) are a broad family of virusesthat
includes SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-
NL63 and HCoV-HKU1 strains. HCoV-229E, HCoV-OC43, HCoV-
NL63 and HCoV-HKU1 strains are usually associated with mild,
self-limiting upper respiratory tract infections, such as the
common cold. By contrast, people infected with MERS-CoV,
SASRS-CoV or SARS-CoV-2 could develop severe respiratory illness,
and many of the infected have died.No vaccines and drugs are available for prevention, prophylaxis
and treatment of coronavirus infections in humans (Eurosurveil-
lance Editorial, 2020). However, safe-in-man BSAAs could be
effective against SARS-CoV-2 and other coronaviruses (Figure 5).
For example, teicoplanin, oritavancin, dalbavancin, monensin and
emetine could be repurposed for treatment of COVID-19.
Teicoplanin, ritavancin, dalbavancin and monensin are approved
antibiotics, whereas emetine is an anti-protozoal drug. These drugs
have been shown to inhibit several corona- as well as some other
viral infections . Moreover, chloroquine and remdesivir were
shown to effectively inhibit SARS-CoV-2 infection in vitro. In
addition, clinical investigations into the effectiveness of lopinavir,
ritonavir, remdesivir, hydroxychloroquine and arbidol against
COVID-19 have started recently (NCT04252664; NCT0425487;
NCT04255017; NCT04261517, NCT04260594).
BSAA combinations
BSAAs could be combined with other antiviral agents to obtain
synergistic or additive effects against certain viruses (Cheng et al.,
2019; Zheng et al., 2018). Several combination therapies which
Figure 5. Safe-in-man broad-spectrum antiviral agents and coronaviruses they
inhibit. A snapshot is taken from https://drugvirus.info/ website. Different shadings
indicate different development status of BSAAs. Grey shading indicates that the
antiviral activity has not been either studied or reported.
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meq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza),
lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir and sofosbu-
vir/velpatasvir) became a standard for the treatment of HIV or HCV
infections. Several synergistic drug combinations, such as obato-
clax/saliphenylhalamide and gemcitabine/pimodivir, could enter
clinical studies and become effective treatment of ZIKV and FLUAV
infections (Fu et al., 2016; Kuivanen et al., 2017).
By contrast to individual drugs, combinations of 2–3 BSAAs
could be used to target an even broader range of viruses (Foucquier
and Guedj, 2015; Zheng et al., 2018). Such combinations could
serve as front line therapeutics against poorly characterized
emerging viruses or re-emerging drug-resistant viral strains. For
example, a cocktail of nitazoxanide, favipiravir, and niclosamide
could be developed for the treatment of viruses belonging to 11
families.
Other activities of BSAAs
Fifty BSAAs possess not only antiviral but also antibacterial
activity (Figure 4; Table S1) (Schor and Einav, 2018). Moreover, 13
of the 50 agents are approved as antibiotics (2 withdrawn). Theseagents with dual activity could be used for treatment of viral and
bacterial co-infections or for the protection of patients from the
secondary infections. For example, azithromycin could be used
against FLUAV and Chlamydophila pneumoniae, Haemophilus
influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae
infections (NCT01779570) (Mandell et al., 2007).
In addition, BSAAs showed activity against a wide range of
other medically important human pathogens, including fungi,
protozoa and parasites (Table S1) (Montoya and Krysan, 2018),
pointing out that some pathogens utilize common mechanisms
to infect hosts. Moreover, structure-activity relationship analysis
of BSAAs suggests that some agents, such as doxycycline,
artesunate, omeprazole, nitazoxanide, suramin, azithromycin,
minocycline and chloroquine, could have novel antibacterial,
antiprotozoal, antifungal or anthelmintic activities (Figure 4). If
confirmed, this could lead to development of broad-spectrum
anti-infective drugs.
BSAAs could also serve as treatment of other co-morbidities,
therefore, simplifying the therapy and lowering its cost (Table S1). For
example, the concomitant actions of ezetimibe and statins could be
beneficial for treatment of both hypertension and several viral
infections in patients with these co-morbidities (NCT00908011,
NCT00099684, NCT00843661, NCT03490097, NCT00994773,
NCT00441493).
Conclusions and future perspectives
Here we reviewed a process of BSAA development and
summarized information on 120 safe-in-man agents in freely
available database. We hope that further pre-clinical and clinical
studies on BSAAs will be harmonized, and data collection will be
standardized. Furthermore, the follow-up studies as well as the
results of on-going, finalized or terminated clinical trials will be
made publicly available to allow prioritization and translation of
emerging and existing BSAAs into clinical practice. This would
allow BSAAs to play a pivotal role in the battle against emerging
and re-emerging viral diseases.
Discovery of novel as well as repositioning existing safe-in-man
BSAAs may shorten time and resources needed for development of
virus-specific drugs and vaccines. In the future, BSAAs will have a
global impact by decreasing morbidity and mortality from viral and
other diseases, maximizing the number of healthy life years,
improving the quality of life of infected patients and decreasing the
costs of patient care.
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